Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

March 6, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Metastatic CancerCarcinomaAdenocarcinoma
Interventions
DRUG

18F-Clofarabine

The participants enrolled will receive a baseline CFA PET/CT evaluation. Then, the participants will undergo the routine follow up would normally occur for their cancer and its treatment. If this routine follow up and care involves repeat imaging of the cancer, then the CFA PET/CT scan will be repeated at that time (timed according to standard-of-care follow-up imaging), which is expected between a month to about 4 months after the first CFA PET/CT scan. The study period will end 24 hours after this repeat PET/CT scan.

Trial Locations (1)

44106

RECRUITING

Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Roberto Vargas

OTHER